Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR17 | Q13304 | 1/20 | 0.71 |
| ▸ | BCL2 | P10415 | 1/20 | 0.54 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9187231 | 0.88 | GPR17 (0.74) | GPR17 | |
| SCHEMBL6168947 | 0.85 | GPR17 (0.53) | GPR17 | |
| SCHEMBL31025926 | 0.84 | GPR17 (0.72) | GPR17BCL2MCL1 | |
| SCHEMBL3239036 | 0.83 | GPR17 (1.00) | GPR17 | |
| SCHEMBL9449317 | 0.82 | ALOX15 (0.65) | — | |
| SCHEMBL9449473 | 0.81 | GPR17 (0.77) | GPR17BCL2MCL1 | |
| SCHEMBL9449527 | 0.80 | GPR17 (0.60) | GPR17BCL2MCL1 | |
| SCHEMBL3069354 | 0.79 | KDM4E (0.68) | MCL1 | |
| SCHEMBL31025882 | 0.79 | GPR17 (0.65) | GPR17BCL2MCL1 | |
| SCHEMBL15622821 | 0.79 | GPR17 (0.73) | GPR17BCL2MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5229413-A | Nervous system disorders | G. D. SEARLE & CO. (US) | 1993-07-20 | — | — | US | claimed |
| EP-0396124-A2 | Compositions containing indole-2-carboxylate compounds for treatment of CNS disorders | G.D. Searle & Co. (US) | 1990-11-07 | — | — | EP | claimed |
| US-20250288544-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | PARIS SCIENCES ET LETTRES - QUARTIER LATIN (FR) | 2025-09-18 | — | — | US | disclosed |
| US-12318358-B2 | Probenecid for use in treating epileptic diseases, disorders or conditions | PARIS SCIENCES ET LETTRES (FR) | 2025-06-03 | — | — | US | disclosed |
| CN-111386107-A | Use of probenecid in the treatment of an epileptic disease, disorder or condition | 巴黎科技与文学─拉丁区 | 2020-07-07 | — | — | CN | disclosed |
| US-20200163916-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | PARIS SCIENCES ET LETTRES - QUARTIER LATIN (FR) | 2020-05-28 | — | — | US | disclosed |
| EP-3651758-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | Paris Sciences et Lettres - Quartier Latin (FR) | 2020-05-20 | — | — | EP | disclosed |
| WO-2019012109-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | PARIS SCIENCES ET LETTRES - QUARTIER LATIN (FR) | 2019-01-17 | — | — | WO | disclosed |
| US-5229413-A | Nervous system disorders | G. D. SEARLE & CO. (US) | 1993-07-20 | — | — | US | disclosed |
| US-5137910-A | Compositions containing indole-2-carboxylate compounds for treatment of CNS disorders | C.D. SEARLE & CO. (US) | 1992-08-11 | — | — | US | disclosed |
| EP-0396124-A2 | Compositions containing indole-2-carboxylate compounds for treatment of CNS disorders | G.D. Searle & Co. (US) | 1990-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200163916-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | NLN, CLN6, SLC1A2 | GPR17 1618/4885BCL2 2909/4885MCL1 4656/4885 |
| US-20250288544-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | NLN, CLN6, SLC1A2 | GPR17 1618/4885BCL2 2909/4885MCL1 4656/4885 |
| US-12318358-B2 | Probenecid for use in treating epileptic diseases, disorders or conditions | NLN, CLN6, SLC1A2 | GPR17 1618/4885BCL2 2909/4885MCL1 4656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.